No abstract is available for this article. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the present study. References 1, , et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026; 395: 338–348 2, , et al. EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Edn. Presented at the EAU Annual Congress London. Arnhem, The Netherlands: EAU Guidelines Office, 2026.
Matteo Ferro
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Matteo
Contact Matteo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack